Immunology Market to Surge at 12% CAGR over 2024 to 2032; Pfizer Inc. Completed the Acquisition of Arena Pharmaceuticals to Boost its Product Portfolio

The global immunology market size stood at USD 98.47 billion in 2023. The market value is poised to rise from USD 106.11 billion in 2024 to USD 263.56 billion by 2032 at a CAGR of 12% during 2024-2032.

Fortune Business Insights™ presents this information in its report titled “Immunology Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Monoclonal Antibody (mAb), Fusion Proteins, Immunosuppressants, and Others), By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2024-2032”.

Immunology drugs or agents modify the immune system's response, enhancing it to combat infections or suppressing it to treat immunological or autoimmune disorders such as rheumatoid arthritis and psoriatic arthritis. The increasing awareness pertaining to immunological diseases, spanning both developed and developing nations, is a driving force behind the growing demand for immunological drugs and treatments.

Impact of the COVID-19 Pandemic on Revenues Led to Slower Market Growth

The COVID-19 pandemic caused revenue decline for some market players, such as Merck & Co., Inc., leading to slower global market growth during 2019-2020. The disruption caused by the pandemic affected sales and operations. Moreover, regulatory delays for drug approvals, patent expirations, increased biosimilar use during the outbreak, and disrupted patient healthcare visits contributed to slower market expansion.

AbbVie collaborated and Signed an Option-To-License Agreement with HotSpot Therapeutics, Inc. for the Autoimmune Diseases Treatments

In December 2022, AbbVie entered into an exclusive global collaboration and option to license agreement with HotSpot Therapeutics, Inc. This strategic partnership encompassed HotSpot's early-stage IRF5 program, dedicated to developing therapies for autoimmune diseases and cancer.

Growing Occurrence of Autoimmune Diseases to Spur Market Progress

The rise in awareness regarding autoimmune diseases, observed in both developed and developing regions, is pivotal in driving market growth. As more people and healthcare providers recognize these conditions, higher demand for immunological drugs and treatments drives market growth. Moreover, the significant expansion of drug development portfolios by key industry players, such as Sanofi and Johnson & Johnson Services, Inc., with numerous projects and candidates targeting autoimmune indications, is another factor promoting market growth.

However, the substantial expenses associated with research and development, drug manufacturing, and clinical trials could hinder immunology market growth. 

Key Players Strike Partnership to Solidify their Market Positions

The current market landscape exhibits consolidation, characterized by major players such as Janssen Global Services, LLC, Amgen, Pfizer, Novartis AG, and AbbVie Inc.  These industry participants strongly focus on pharmaceutical research and development, strategically acquiring domestic firms to solidify their position.

List of Key Players Profiled in the Report:

• AbbVie, Inc. (U.S.)


• Janssen Global Services, LLC (U.S.)


• Eli Lilly and Company (U.S.)


• Novartis AG (Switzerland)


• Pfizer Inc. (U.S.)


• Bristol-Myers Squibb Company (U.S.)


• Merck Sharp & Dohme Corp. (U.S.)


• F. Hoffmann-La Roche Ltd. (Switzerland)


• Amgen Inc. (U.S.)


• Astellas Pharma Inc. (Japan)


• UCB SA (Belgium)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/immunology-market-100657

Key Industry Development

• March 2022 - Pfizer Inc. acquired Arena Pharmaceuticals, a company that develops innovative therapies for various immuno-inflammatory diseases. This strategic move aimed to expand its offerings in the field of immunology.

Further Report Findings

• North America maintained a commanding presence holding a leading immunology market share in 2022 and is anticipated to experience significant CAGR over the projected period. The region’s growth is due to the high prevalence of chronic illnesses such as autoimmune diseases and other immunological disorders.


• Asia Pacific market is expected to grow at the highest CAGR over the analysis period. The region has a substantial population affected by autoimmune disorders and other immunological conditions. This large patient pool drives demand for immunology drugs, driving market growth.

Table of Segmentation